UCB SA (OTCMKTS:UCBJY) Sees Significant Increase in Short Interest

UCB SA (OTCMKTS:UCBJY) was the target of a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 22,078 shares, an increase of 8,231.3% from the May 14th total of 265 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 59,267 shares, the short-interest ratio is presently 0.4 days.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Zacks Research downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 13th. Wolfe Research raised shares of UCB to a “strong-buy” rating in a research note on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy”.

UCB Stock Performance

Shares of UCBJY opened at $151.74 on Wednesday. UCB has a 1-year low of $89.00 and a 1-year high of $168.76. The company has a 50-day moving average of $145.41 and a 200 day moving average of $146.78. The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.